{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:51:25Z","timestamp":1791931885817,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1038\/ijo.2013.120","type":"journal-article","created":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T06:52:11Z","timestamp":1372661531000},"page":"1443-1451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":697,"title":["Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study"],"prefix":"10.1038","volume":"37","author":[{"name":"on behalf of the NN8022-1923 Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T A","family":"Wadden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Niswender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P M","family":"Hale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Aronne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,1]]},"reference":[{"key":"BFijo2013120_CR1","unstructured":"World Health Organization. Obesity: preventing and managing the global epidemic. Geneva, Switzerland: World Health Organization, 1998."},{"issue":"Suppl 2","key":"BFijo2013120_CR2","first-page":"51S","volume":"6","author":"National Institutes of Health","year":"1998","unstructured":"National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. Obes Res 1998; 6 (Suppl 2): 51S\u2013209S.","journal-title":"Obes Res"},{"key":"BFijo2013120_CR3","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.2337\/diacare.25.12.2165","volume":"25","author":"Diabetes Prevention Program (DPP) Research Group","year":"2002","unstructured":"Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002; 25: 2165\u20132171.","journal-title":"Diabetes Care"},{"key":"BFijo2013120_CR4","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.111.039453","volume":"125","author":"TA Wadden","year":"2012","unstructured":"Wadden TA, Webb VL, Moran CH, Bailer BA . Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy. Circulation 2012; 125: 1157\u20131170.","journal-title":"Circulation"},{"key":"BFijo2013120_CR5","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1001\/archinte.1995.00430130102011","volume":"155","author":"RR Wing","year":"1995","unstructured":"Wing RR, Jeffery RW, Hellerstedt WL . A prospective study of effects of weight cycling on cardiovascular risk factors. Arch Intern Med 1995; 155: 1416\u20131422.","journal-title":"Arch Intern Med"},{"key":"BFijo2013120_CR6","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa061883","volume":"355","author":"RR Wing","year":"2006","unstructured":"Wing RR, Tate DF, Gorin AA, Raynor HA, Fava JL . A self-regulation program for maintenance of weight loss. N Engl J Med 2006; 355: 1563\u20131571.","journal-title":"N Engl J Med"},{"key":"BFijo2013120_CR7","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1001\/jama.299.10.1139","volume":"299","author":"LP Svetkey","year":"2008","unstructured":"Svetkey LP, Stevens VJ, Brantley PJ, Appel LJ, Hollis JF, Loria CM et al. Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial. JAMA 2008; 299: 1139\u20131148.","journal-title":"JAMA"},{"key":"BFijo2013120_CR8","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/oby.2011.230","volume":"19","author":"TA Wadden","year":"2011","unstructured":"Wadden TA, Neiberg RH, Wing RR, Clark JM, Delahanty LM, Hill JO et al. Four-year weight losses in the Look AHEAD study: factors associated with long-term success. Obesity 2011; 19: 1987\u20131998.","journal-title":"Obesity"},{"key":"BFijo2013120_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3945\/ajcn.111.024927","volume":"95","author":"WT Garvey","year":"2012","unstructured":"Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95: 297\u2013308.","journal-title":"Am J Clin Nutr"},{"key":"BFijo2013120_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","volume":"352","author":"L Sjostrom","year":"1998","unstructured":"Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167\u2013173.","journal-title":"Lancet"},{"key":"BFijo2013120_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jama.281.3.235","volume":"281","author":"MH Davidson","year":"1999","unstructured":"Davidson MH, Hauptman J, Digirolamo M, Foreyt JP, Halsted CH, Heber D et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial. JAMA 1999; 281: 235\u2013242.","journal-title":"JAMA"},{"key":"BFijo2013120_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0002-9343(98)00411-2","volume":"106","author":"M Apfelbaum","year":"1999","unstructured":"Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E . Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106: 179\u2013184.","journal-title":"Am J Med"},{"key":"BFijo2013120_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1056\/NEJMoa0909809","volume":"363","author":"SR Smith","year":"2010","unstructured":"Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245\u2013256.","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"BFijo2013120_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1463-1326.2009.01075.x","volume":"11","author":"L Blonde","year":"2009","unstructured":"Blonde L, Russell-Jones D . The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009; 11 (Suppl 3): 26\u201334.","journal-title":"Diabetes Obes Metab"},{"key":"BFijo2013120_CR15","unstructured":"Summary of product characteristics, Victoza 2012, \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001026\/WC500050017.pdf\n                    \n                   Accessed 14 Nov 2012."},{"key":"BFijo2013120_CR16","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606\u20131616.","journal-title":"Lancet"},{"key":"BFijo2013120_CR17","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/ijo.2011.158","volume":"36","author":"A Astrup","year":"2012","unstructured":"Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes 2012; 36: 843\u2013854.","journal-title":"Int J Obes"},{"issue":"23","key":"BFijo2013120_CR18","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1001\/jama.284.23.3043","volume":"284","author":"Not Available","year":"2000","unstructured":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000; 284: 3043\u20133045.","journal-title":"JAMA"},{"key":"BFijo2013120_CR19","unstructured":"International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice. 1-May- 1996, \n                    http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6_R1\/Step4\/E6_R1_Guideline.pdf\n                    \n                   Accessed 14 Nov 2012."},{"key":"BFijo2013120_CR20","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.jpsychires.2010.04.025","volume":"44","author":"JC Mundt","year":"2010","unstructured":"Mundt JC, Greist JH, Gelenberg AJ, Katzelnick DJ, Jefferson JW, Modell JG et al. Feasibility and validation of a computer-automated Columbia-Suicide severity rating scale using interactive voice response technology. J Psychiatr Res 2010; 44: 1224\u20131228.","journal-title":"J Psychiatr Res"},{"key":"BFijo2013120_CR21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB . The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606\u2013613.","journal-title":"J Gen Intern Med"},{"key":"BFijo2013120_CR22","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1093\/clinchem\/39.12.2495","volume":"39","author":"JP Corsetti","year":"1993","unstructured":"Corsetti JP, Cox C, Schulz TJ, Arvan DA . Combined serum amylase and lipase determinations for diagnosis of suspected acute pancreatitis. Clin Chem 1993; 39: 2495\u20132499.","journal-title":"Clin Chem"},{"key":"BFijo2013120_CR23","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/oby.2004.206","volume":"12","author":"A Astrup","year":"2004","unstructured":"Astrup A, Caterson I, Zelissen P, Guy-Grand B, Carruba M, Levy B et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004; 12: 1658\u20131669.","journal-title":"Obes Res"},{"key":"BFijo2013120_CR24","unstructured":"Food and Drug Administration. FDA Guidance for Industry: Developing products for weight management, 2007, \n                    http:\/\/www.fda.gov\/downloads\/Drugs\/...\/Guidances\/ucm071612.pdf\n                    \n                   Accessed 14 Nov 2012."},{"key":"BFijo2013120_CR25","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/ajcn\/69.6.1108","volume":"69","author":"JO Hill","year":"1999","unstructured":"Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: A 1-y study. Am J Clin Nutr 1999; 69: 1108\u20131116.","journal-title":"Am J Clin Nutr"},{"key":"BFijo2013120_CR26","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1056\/NEJMoa050156","volume":"353","author":"TA Wadden","year":"2005","unstructured":"Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 2111\u20132120.","journal-title":"N Engl J Med"},{"key":"BFijo2013120_CR27","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jama.286.11.1331","volume":"286","author":"A Wirth","year":"2001","unstructured":"Wirth A, Krause J . Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286: 1331\u20131339.","journal-title":"JAMA"},{"key":"BFijo2013120_CR28","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/bmj.1.5588.352","volume":"1","author":"JF Munro","year":"1968","unstructured":"Munro JF, MacCusih AC, Wilson EM, Duncan LJ . Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J 1968; 1: 352\u2013354.","journal-title":"Br Med J"},{"key":"BFijo2013120_CR29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/j.1550-8528.1999.tb00699.x","volume":"7","author":"TA Wadden","year":"1999","unstructured":"Wadden TA, Anderson DA, Foster GD . Two-year changes in lipids and lipoproteins associated with the maintenance of a 5 to 10% reduction in initial weight: some findings and some questions. Obes Res 1999; 7: 170\u2013178.","journal-title":"Obes Res"},{"key":"BFijo2013120_CR30","first-page":"1287","volume":"77","author":"DE Kelley","year":"1993","unstructured":"Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M . Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 1287\u20131293.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFijo2013120_CR31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1479164111408937","volume":"8","author":"SP Marso","year":"2011","unstructured":"Marso SP, Lindsey JB, Stolker JM, House JA, Martinez RG, Kennedy KF et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res 2011; 8: 237\u2013240.","journal-title":"Diab Vasc Dis Res"},{"key":"BFijo2013120_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"NCEP report","year":"2004","unstructured":"NCEP report. Implications of recent clinical trials for the national cholesterol education program Adult Treatment Panel III guidelines Endorsed by the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association. Circulation 2004; 110: 227\u2013239.","journal-title":"Circulation"},{"key":"BFijo2013120_CR33","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","volume":"109","author":"SM Grundy","year":"2004","unstructured":"Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C . Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute\/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109: 433\u2013438.","journal-title":"Circulation"},{"key":"BFijo2013120_CR34","doi-asserted-by":"crossref","unstructured":"The Seventh Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute. JAMA 2003; 289: 2560\u20132572.","DOI":"10.1001\/jama.289.19.2560"}],"updated-by":[{"DOI":"10.1038\/ijo.2013.148","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2013,9,3]],"date-time":"2013-09-03T00:00:00Z","timestamp":1378166400000}},{"DOI":"10.1038\/ijo.2014.88","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T00:00:00Z","timestamp":1413244800000}}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ijo2013120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ijo2013120","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ijo2013120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:28:51Z","timestamp":1684416531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ijo2013120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,1]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["BFijo2013120"],"URL":"https:\/\/doi.org\/10.1038\/ijo.2013.120","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,1]]},"assertion":[{"value":"5 December 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2013","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been corrected since online publication and an erratum is also printed in this issue","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PMH is an employee of Novo Nordisk, and also owns stock in the company. TAW serves on advisory boards for Novo Nordisk and Orexigen Pharmaceuticals. PH serves on an advisory board and is a consultant for Novo Nordisk. SK is a consultant for Takeda Pharmaceuticals and Vivus. KN is a consultant for Novo Nordisk and has done commercially sponsored research for Novo Nordisk. VW serves on advisory boards, has held paid lectures or has done commercially sponsored research for Novo Nordisk, Eli Lilly, Sanofi, Bristol-Myers Squibb, AstraZeneca and Boehringer Ingelheim. LA is a consultant or receives research support from Amylin Pharmaceuticals, F Hoffman-La Roche, Abbott Laboratories, Ethicon Endo-Surgery, Orexigen Therapeutics, Vivus, GlaxoSmithKline Consumer Healthcare, LP, Takeda Pharmaceuticals and Zafgen. He has ownership interest in Cardiometabolic Support Network, LLC and Atlas Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}